Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

Andrew X. Zhu; Richard S. Finn; Peter R. Galle; Josep M. Llovet; Masatoshi Kudo

doi:10.1016/s1470-2045(19)30165-2

Related publications

Article2020

Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

Peter R. Galle, Masatoshi Kudo, Josep M. Llovet, Richard S. Finn, Mark Karwal, Denis Pezet, Tae‐You Kim, Tsai‐Sheng Yang, Vittorina Zagonel, Jiří Tomášek, Jean-Marc Phélip, Yann Touchefeu, Su‐Jin Koh, Guido Stirnimann, Chunxiao Wang, Kenyon D. Ogburn, Paolo Abada, Ryan C. Widau, Andrew X. Zhu

Journal of Hepatology

Article2019

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Andrew X. Zhu, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Yoon‐Koo Kang, Chung‐Jen Yen, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Tim Meyer, Ryan C. Widau, William R. Schelman, C. Wang, Yanzhi Hsu, Masatoshi Kudo

Annals of Oncology

Article2021

Ramucirumab in patients with advanced hepatocellular carcinoma and elevated <i>α</i>‐fetoprotein: Outcomes by treatment‐emergent ascites

Masatoshi Kudo, Masafumi Ikeda, Peter R. Galle, Tatsuya Yamashita, Richard S. Finn, Kun Liang, Chunxiao Wang, Sachi Sakaguchi, Paolo Abada, Ryan C. Widau, Andrew X. Zhu

Article2020

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu

Liver International

Article2019

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto,